When uncontrolled, atopic dermatitis (AD) can impose a large clinical burden on the patient—adversely affecting sleep, work, relationships, and overall daily living. This extract video will review the key drivers, symptoms, and coping mechanisms for AD; define adequate disease control and review systemic solutions for uncontrolled disease.

Large randomized clinical trials established non-vitamin K antagonist oral anticoagulants (NOACs) as the guideline-recommended standard of care for preventing stroke in patients with atrial fibrillation. More recently, the ETNA-AF Global Registry further substantiated the safety and efficacy of NOACs in an all-comer population including the elderly and frail.

Early nutrition plays a key role in the development of an infant’s gastrointestinal (GI) microbiota thus, also supporting the development of immunoprotective functions. Bioactive components found in human milk such as prebiotics, probiotics, and nucleotides are key factors in shaping the infant’s intestinal immune system, which makes up more than 80% of the body’s immune cells. The relationship between nutrition, gut microbiota and the immune system has led to recent advances in infant formula microbiota-targeted therapeutics. More specifically, this program will review the role of human milk oligosaccharides (HMOs) on the growth of gut microbiota and immune-modulation, and the systemic beneficial effects that they confer.

This eXtract video features the expert opinion of Dr. Danielle Vicus on the prevention of venous thromboembolism (VTE) in patients undergoing gynecologic surgery. The engaging format is meant to highlight relevant topics regarding the use of extended dual prophylaxis, it’s supporting evidence as well as current guidelines for gynecologic malignancy surgery, such as cervical, endometrial, or ovarian cancer.

In recent years, treat & extend (T&E) regimens have become the treatment strategy most used by retina specialists. ALTAIR was the first RCT to push the boundaries of T&E regimens by examining in detail the outcomes associated with 4-week adjustments and injection intervals beyond 12 weeks. The recently published 96-week data further substantiates the safety and efficacy of the proactive, flexible T&E regimens.

In this eLearning program, the role of monoclonal antibodies in the treatment of multiple sclerosis will be evaluated in the context of newly-completed phase 3 trials with ofatumumab, including the ASCLEPIOS I and II studies.

This eXtract video features key information from the EULAR Congress of Rheumatology 2020 eCongress. This year’s conference released data on more treatment options for moderate-to-severe rheumatoid arthritis across an expanding list of drug classes, including a recently-approved selective oral JAK inhibitor. This quick tour with an expert focuses on results from SELECT-CHOICE and expanded data from SELECT-COMPARE— the only comparative trials for rheumatoid arthritis therapies presented at EULAR. This video will focus on the efficacy and safety of newer oral therapies in light of these new head-to-head trials and the latest options available to patients to individualize their therapy based on their own preferences.

Tyrosine kinase inhibitors (TKI) active against epidermal growth factor receptor (EGFR) are a standard of care in EGFR-mutated non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations. With the introduction of first, second, and third generation TKIs, the role of TKIs has and continues to evolve. In this program, a brief history of TKIs in NSCLC will lead to a review of current strategies relative to clinical features of EGFR-mutated NSCLC. These will be discussed in the context of the recently released Canadian Consensus guidelines. The potential future directions in the treatment of EGFR-mutated NSCLC will be evaluated in relation to on-going studies.

This quick tour with an expert focuses on the prevention of venous thromboembolism (VTE) in patients with gynecologic malignancies, specific to the context of the COVID-19 pandemic. The engaging format is meant to highlight best clinical practices in regards to the use of thromboprophylaxis in higher risk patients.

This eXtract video features key information from the European Academy of Neurology (EAN) Virtual Congress. This quick tour with an expert focuses on the latest data from the EXPAND open-label extension trial and newly released substudies from the core trial. More specifically, this video will focus on the long-term 5-year safety and efficacy results including disability and cognitive outcomes as well as treatment effects on myelin and brain tissue structures such as thalamic atrophy and cortical grey matter loss.